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Type 2 diabetes mellitus (T2DM) is highly predictive of cardiovascular diseases and can have particularly deleterious health impacts in people
with severe mental illness (SMI), i.e. schizophrenia, bipolar disorder or major depressive disorder. This meta-analysis aimed: a) to describe
pooled frequencies of T2DM in people with SMI; b) to analyze the influence of demographic, illness and treatment variables as well as T2DM
assessment methods; and c) to describe T2DM prevalence in studies directly comparing persons with each specific SMI diagnosis to general
population samples. The trim and fill adjusted pooled T2DM prevalence among 438,245 people with SMI was 11.3% (95% CI: 10.0%-12.6%).
In antipsychotic-na€ıve participants, the prevalence of T2DM was 2.9% (95% CI: 1.7%-4.8%). There were no significant diagnostic subgroup dif-
ferences. A comparative meta-analysis established that multi-episode persons with SMI (N5133,470) were significantly more likely to have
T2DM than matched controls (N55,622,664; relative risk, RR51.85, 95% CI: 1.45-2.37, p<0.001). The T2DM prevalence was consistently ele-
vated in each of the three major diagnostic subgroups compared to matched controls. Higher T2DM prevalences were observed in women with
SMI compared to men (RR51.43, 95% CI: 1.20-1.69, p<0.001). Multi-episode (versus first-episode) status was the only significant predictor for
T2DM in a multivariable meta-regression analysis (r250.52, p<0.001). The T2DM prevalence was higher in patients prescribed antipsychotics,
except for aripriprazole and amisulpride. Routine screening and multidisciplinary management of T2DM is needed. T2DM risks of individual
antipsychotic medications should be considered when making treatment choices.
Key words: Diabetes mellitus, severe mental illness, schizophrenia, bipolar disorder, major depressive disorder, antipsychotics
(World Psychiatry 2016;15:00-00)
People with severe mental illness (SMI) – defined as schizo-
phrenia, bipolar disorder or major depressive disorder (MDD) –
have a two to three times higher risk for premature death than
the general population1,2. This mortality gap translates to a
10-20 year shortened life expectancy3,4 and appears to be
widening5. The most important cause for this shortened life
expectancy is cardiovascular disease (CVD)6. Major risk factors
include antipsychotic medication use and an unhealthy life-
style7, and these risks are compounded by obstacles in access
to medical care8-12.
Type 2 diabetes mellitus (T2DM) is a major risk factor for
CVD. It confers an about two-fold excess risk for coronary
heart disease, major stroke subtypes, and deaths attributed to
other vascular causes13,14. Prevention and treatment of T2DM
demands careful consideration in clinical practice, particularly
in populations with an increased risk for CVD and associated
premature mortality15,16.
Recent meta-analyses17-20 demonstrated that all diagnostic
SMI subgroups have a higher risk for developing T2DM than
the general population. However, meta-analytic data compar-
ing T2DM risks across different psychiatric diagnoses are
currently lacking. Furthermore, there are no meta-analytic
data that combine all major diagnostic SMI subgroups, and
information on the prevalence of T2DM among people with
SMI prescribed different antipsychotic medication classes is
insufficient.
Large-scale pooled analyses in the SMI population are rele-
vant, as they enable investigation of risk factors across large
numbers of studies and participants, distinguishing risk fac-
tors for T2DM associated with specific SMIs from those
independent of these illnesses. Pooling data across major
diagnostic categories allows for investigation of the effect of
demographic variables (gender, age, illness duration, study set-
ting, geographical region) and treatments (particularly mood
stabilizers and antipsychotics prescribed for psychotic and
non-psychotic conditions). If risk stratification is observed,
this could potentially guide clinicians in monitoring and
treatment.
Given the aforementioned gaps within the literature, we
conducted a large scale systematic review and meta-analysis
of pooled T2DM prevalences in people with schizophrenia or
related psychotic disorders, bipolar disorder or MDD. We
aimed to: a) describe pooled T2DM frequencies in people with
SMI; b) analyze the influence of demographic, illness and
treatment variables as well as T2DM assessment methods; and
c) describe T2DM prevalence in studies directly comparing
persons with each specific SMI diagnosis to general popula-
tion samples.
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METHODS
Inclusion and exclusion criteria
This systematic review was conducted in accordance with the
Meta-analysis of Observational Studies in Epidemiology (MOOSE)
guidelines21 and in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) standard22.
We included observational studies (cross-sectional, retro-
spective and prospective studies) and randomized controlled
trials in adults with a psychiatric diagnosis of schizophrenia or
related psychotic disorders, bipolar disorder or MDD accord-
ing to the DSM-IV-TR or the ICD-10, irrespective of clinical
setting (inpatient, outpatient or mixed, community setting),
that reported study-defined T2DM prevalences.
We excluded studies restricted to patients with or without
cardiovascular diseases. When required, we contacted the pri-
mary or corresponding authors of studies to confirm eligibility,
and to obtain the data needed for analysis if they were not
available in the published paper.
Search criteria, study selection and critical appraisal
Two independent reviewers (DV, BS) searched Medline, Psy-
cARTICLES, Embase and CINAHL from database inception to
August 1, 2015, without language restrictions. Key words used
were “diabetes” OR “glucose” AND “severe mental illness” OR
“serious mental illness” OR “schizophrenia” OR “psychosis”
OR “bipolar disorder” OR “depression” OR “depressive disor-
der” in the title, abstract or index term fields. Manual searches
were also conducted using the reference lists from recovered
articles and recent systematic reviews.
After the removal of duplicates, the reviewers screened the
titles and abstracts of all potentially eligible articles. They both
applied the eligibility criteria, and a list of full text articles was
developed through consensus. Next, the two reviewers consid-
ered the full texts of these articles and the final list of included
articles was reached through consensus. A third reviewer (CC)
was available for mediation throughout this process. Method-
ological appraisal included evaluation of bias (confounding,
overlapping data, publication bias).
Statistical analyses
Due to anticipated heterogeneity, a random effects meta-
analysis was employed. Heterogeneity was measured with the
Q statistic (which is always presented at the end of the
description of the results as a second or final p-value).
We calculated the relative risk (RR) to investigate the T2DM
prevalence within and across SMI subgroups, the latter only in
those studies directly comparing diagnostic subgroups. More-
over, we compared the prevalence of T2DM between people
with schizophrenia, bipolar disorder and MDD and general
population control groups that were matched on age and sex,
using data from studies in which they were directly compared.
In both analyses, only comparisons of specific SMI groups or a
SMI group with a matched general population group were
included that had been performed within the same study, in
order to minimize variability of T2DM frequencies due to dif-
ferent sampling and assessment procedures.
Furthermore, in the entire dataset, we conducted subgroup
analyses to investigate differences between the three main diag-
nostic subgroups, first-episode versus multi-episode illness,
males versus females, population based versus non-population
based studies, and differences across medication classes (anti-
psychotics, antidepressants, mood stabilizers) and geographical
regions. In order to reduce heterogeneity, we did not calculate
diagnostic and gender differences across studies, but pooled
only data of studies that compared these differences on a patient
level. Further, we conducted meta-regression analyses to investi-
gate potential moderators (age, percentage of males, illness
duration, smoking prevalence, and T2DM assessment methods)
with Comprehensive Meta Analysis (version 3).
Publication bias was tested using the Egger’s regression
method23 and Begg-Mazumdar test24, with a p-value <0.05
suggesting the presence of bias. When we encountered publi-
cation bias, we conducted a trim and fill adjusted analysis25
to remove the most extreme small studies from the positive
side of the funnel plot, and recalculated the effect size itera-
tively, until the funnel plot was symmetrical around the (new)
effect size.
RESULTS
Search results and included participants
After excluding duplicates and irrevelant hits, our search
yielded 323 publications, of which 118 (including 135 T2DM
prevalences) met inclusion criteria (Figure 1). A list of the
included and excluded studies (with reasons) is available upon
request from the first author.
The final sample comprised 438,245 unique persons with
SMI and 5,622,664 matched controls. Sample sizes ranged
from 12 to 143,943 participants, with a median sample size of
270. The mean age of participants with SMI was 44.3 years
(range 23.1-77.6 years); 56.8% were male (range 0-100); 69%
were Caucasian (range 0-100; 37 studies). Mean illness dura-
tion was 16.1 years (range 0-35 years; 29 studies). Thirty-one
studies (N577,028) reported smoking frequencies, and 44.5%
(95% CI: 29.2%-60.4%) of the included participants smoked.
T2DM prevalence
The estimated weighted mean prevalence of T2DM among
438,245 people with SMI was 10.2% (95% CI: 9.1%-11.4%;
Q514228.7, p<0.001). The Begg-Mazumdar (Kendall’s tau50.15,
p50.009) and Egger test (bias525.39, 95% CI: 27.33 to 23.45,
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p<0.001) indicated presence of publication bias. Applying the
trim and fill method, adjusting for 13 studies, the prevalence of
T2DMwas 11.3% (95% CI: 10.0%-12.6%).
Subgroup analyses and predictors of T2DM
Study setting and design
The pooled prevalences across different treatment settings
(inpatients, outpatients, community patients, mixed settings),
study designs (cross-sectional, retrospective and prospective
studies, and population versus non-population based), medi-
an year of data collection (before or after the year 2000), meth-
ods of T2DM assessment (blood testing, self-report, charts) are
summarized in Table 1. The separate meta-regressions are pre-
sented in Table 2.
There were no significant differences between the various
treatment settings, and data collection before versus after the
year 2000. There was also no difference in T2DM prevalence
between population based and non-population based studies.
In contrast, a higher T2DM prevalence was observed in studies
relying upon clinical data gleaned from file and chart reviews
versus self-report studies. A trend for higher T2DM was found
in retrospective studies versus cross-sectional (p50.054) and
versus prospective (p50.053) studies.
Diagnostic subgroups
The pooled T2DM prevalences for the different diagnostic
subgroups are presented in Table 1. Relative risk meta-analyses
established that there was no significant difference in T2DM in
studies directly comparing schizophrenia alone (14.1%, 95% CI:
9.8%-20.2%; Q55, p50.51; N54,963) versus schizophrenia
spectrum disorders (including schizoaffective disorder, schizo-
phreniform disorder and related psychoses) (18.3%, 95% CI:
14.9%-22.2%; Q52.1, p50.34; N5694) (three studies; odds ratio,
OR50.80; 95% CI: 0.52-1.25, z520.97, p50.33; Q52.66,
p50.26, I2524.9).
The same was true for the comparison of schizophrenia
(13.7%, 95% CI: 8.2%-22.1%; Q5131, p<0.01; N56,005) versus
bipolar disorder (13.7%, 95% CI: 9.2%-20.0%; Q546, p<0.01;
N53,138) (six studies; OR51.22, 95% CI: 0.84-1.77, z51.08,
p50.28; Q517.1, p50.004, I2570.8); and of schizophrenia
(13.7%, 95% CI: 11.6%-16.1%; Q50.3, p50.58; N5893) versus
MDD (11.1%, 95% CI: 9.2%-13.3%; N5911) (two studies;
OR51.27, 95% CI: 0.96-1.68, z51.66, p50.10; Q56.0, p50.80,
I250). There were insufficient studies directly comparing
T2DM prevalence in patients with bipolar disorder versus
MDD.
Comparing T2DM in first- versus multi-episode patients
within the different diagnostic subgroups (see Table 1) demon-
strated that first-episode schizophrenia patients (4.0%, 95%
CI: 2.5%-6.2%) had a significantly lower T2DM prevalence
than multi-episode schizophrenia patients (13.1%, 95% CI:
11.7%-14.8%, z523.89, p<0.001). There were no data in first-
episode bipolar disorder or MDD patients, precluding a com-
parison with multi-episode patients.
Demographic variables
A relative risk meta-analysis across 29 studies (including
32 comparisons) directly comparing T2DM frequencies in
men (N535,400) versus women (N533,283) with SMI found a
higher T2DM prevalence in women (RR51.43; 95% CI: 1.20-
1.69, p<0.001).
Pooled T2DM prevalences per geographical region are dis-
played in Table 1. The T2DM prevalence was significantly
higher in North America (12.5%, 95% CI: 10.9%-14.3%; 58 stud-
ies) than in Europe (7.7%, 95% CI: 6.3%-9.3%; 32 studies)
(p<0.001). No other significant geographical differences were
observed.
Separate meta-regression analyses (see Table 2) revealed
that higher T2DM frequencies were moderated by older age,
longer illness duration and first-episode versus multi-episode
status, but not by gender, ethnicity, and smoking status.
When all significant demographic predictors were entered in
a multivariable meta-regression model, multi-episode versus
first-episode status (b51.889, 95% CI: 0.1445-3.6335, z52.12,
p50.03) remained the only significant moderator of the variance
of T2DM. The final multivariable model accounted for just over
Records screened after duplicates and 
irrelevant papers were removed 
(n=323) 
Records excluded on title/abstract level 
(n=125) 
Reasons: only in diabetes patients 
(n=98), review (n=13), conference 
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(n=5), type 1 diabetes (n=1) 
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Figure 1 Flow diagram for the search strategy. T2DM - type 2 diabe-
tes mellitus; SMI - severe mental illness, CVD - cardiovascular
disease
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Table 1 Subgroup analyses of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness
Meta-analysis Heterogeneity
Number
of studies
Pooled T2DM
prevalence (%) 95% CI
Between-group
difference p-value I2 Q p-value
Study design
Cross-sectional 70 9.2 7.9-10.8 0.03 97.2 2504.2 <0.001
Retrospective 43 12.3 10.3-4.8 99.3 6436.5 <0.001
Prospective 21 8.5 6.2-11.5 98.7 1575.0 <0.001
Population based or not
Population based 58 10.0 8.5-11.6 0.70 99.6 13491.3 <0.001
Non-population based 76 10.4 8.9-12.2 84.6 486.0 <0.001
Study setting
Mixed 37 8.7 7.1-10.5 0.26 99.5 7179.8 <0.001
Inpatient 37 11.3 9.3-13.8 93.5 553.7 <0.001
Outpatient 36 11.5 9.3-14.1 97.1 1229.7 <0.001
Community 21 9.7 7.4-12.4 98.4 1221.7 <0.001
Diabetes assessment method
Blood testing 34 10.5 9.8-11.2 <0.001 79.3 159.3 <0.001
Self-report 26 9.3 8.8-9.8 97.4 980.9 <0.001
Charts and files 53 13.0 11.0-15.2 99.5 11051.8 <0.001
Median year data collection
Before 2000 18 9.5 6.9-12.8 97.7 728.6 <0.001
2000 or later 116 10.2 9.0-11.6 99.1 13469.1 <0.001
Diagnosis
Mixed 18 11.2 8.5-14.6 0.003 99.6 4011.7 <0.001
Major depressive disorder 20 6.4 4.8-8.4 97.8 869.4 <0.001
Bipolar disorder 17 9.2 6.8-12.4 96.6 466.8 <0.001
Schizophrenia spectrum 22 11.8 9.0-15.2 99.0 5151.0 <0.001
Schizophrenia only 57 11.5 9.8-13.5 94.7 394.2 <0.001
Episode
First-episode schizophrenia 14 4.0 2.5-6.2 <0.001 62.2 34.4 0.001
Multi-episode schizophrenia 67 13.1 11.7-14.8 98.9 6011.1 <0.001
Gender
Male 31 7.9 5.9-10.3 <0.01 97.0 1037.5 <0.001
Female 31 11.3 8.6-14.7 97.5 1239.8 <0.001
Geographical region
North America 58 12.5 10.9-14.3 0.007 99.0 6026.7 <0.001
Europe 32 7.7 6.3-9.3 98.7 2486.6 <0.001
Asia 28 10.6 8.5-13.1 93.1 393.9 <0.001
Australia 5 9.2 5.7-14.5 90.6 42.7 0.034
South America 5 8.6 4.8-15.1 61.7 10.4 0.006
Africa 2 7.0 3.1-15.0 86.6 7.5 0.65
Middle East 2 10.2 4.8-20.3 0 0.2 0.33
Antipsychotic medication use
Antipsychotic-na€ıve 10 2.9 1.7-4.8 <0.001 78.0 41.0 <0.001
Clozapine 9 15.5 11.0-21.3 38.4 13.0 0.11
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half of the between-study heterogeneity in T2DM frequency
(r250.52, p<0.001).
Medication use
Separate meta-regression analyses (see Table 2) showed
that treatment duration, percentage of antidepressant use and
percentage of lithium use, but not percentage of mood stabil-
izers use, were significant mediators of T2DM prevalence.
Twenty papers, including 64 analyses, reported on antipsy-
chotics (monotherapy) and T2DM frequencies. The prevalence
of T2DM was lowest in antipsychotic-na€ıve participants (2.9%,
95% CI: 1.7%-4.8%). Except for aripiprazole and amisulpride,
all individual antipsychotics had significantly (p<0.05) higher
T2DM risk compared to antipsychotic-na€ıve participants (see
Table 1). Except for a higher risk for quetiapine versus olanza-
pine (p50.04), we did not find any differences in risk profile
between individual medications. The T2DM risk in people
treated with clozapine tended (p50.05) to be higher than the
risk in those treated with olanzapine.
Relative risk (RR) of T2DM in diagnostic subgroups
compared with general population controls
Thirty-four studies provided data on T2DM prevalences
comparing multi-episode patients with healthy control sub-
jects, and three studies compared first-episode schizophrenia
patients with controls. In a pooled relative risk meta-analysis,
compared with general population controls (N55,622,664;
6.2%, 95% CI: 4.8%-8.0%; Q518,592, p<0.01), multi-episode
persons with SMIs (N5133,470; 12.2%, 95% CI: 9.7-15.2%;
Q56166, p<0.01) had significantly increased risk of T2DM
(RR51.85, 95% CI: 1.45-2.37, p<0.001; Q51302.0, p<0.001;
38 studies). There was no significant difference in T2DM in
first-episode patients (4.4%, 95% CI: 2.5%-7.6%; Q52, p50.4)
versus controls (0.9%, 95% CI: 0.03%-2.4%; Q53, p50.3)
(RR54.64, 95% CI: 0.73-29.3, p50.10; Q51302.0, p50.23; three
studies).
Compared to healthy controls, the relative risk of T2DM
was 2.04 in patients with schizophrenia or related psychotic
disorders (N5115,538; 95% CI: 1.69-2.49, p<0.001; Q51302.0,
p<0.001, I2597.8; 29 studies); 1.89 in patients with bipolar
disorder (N54,688; 95% CI: 1.29-2.77, p<0.001; Q52.2, p50.34,
I257.3; six studies), and 1.43 in patients with MDD (N510,895;
95% CI: 0.88-2.25, p50.029; Q52.15, p50.34; three studies).
DISCUSSION
To our knowledge, this is the first meta-analysis of T2DM
including and comparing data from the three main SMIs,
namely schizophrenia spectrum, bipolar disorder and MDD.
Approximately one in 10 individuals with SMI (11.3%; 95% CI:
10.0%-12.6%) had T2DM, and the relative risk for T2DM was
almost double (RR51.85, 95% CI: 1.55-2.37) that found in
matched general population comparison samples.
T2DM prevalences were consistently elevated for each of
the three diagnostic subgroups compared to the general popu-
lation, and comparative meta-analyses found no significant
differences across schizophrenia, schizophrenia spectrum
disorders, bipolar disorder and MDD. Thus, other diagnostic-
independent factors likely influence T2DM frequency, includ-
ing hyperglycaemia following psychotropic medication use26
and long-term exposure to unhealthy lifestyle behaviors27,28,
as well as potential genetic factors linking psychiatric and
medical risk29.
We showed for the first time in a large scale meta-analysis
that T2DM risk indeed increased with increasing treatment
duration, supported further by a multivariate meta-regression
model in which multi-episode status remained a unique sig-
nificant predictor, explaining half of the variance. We also
observed a significantly increased prevalence of T2DM in
North America versus Europe, in keeping with the overall pop-
ulation prevalences30, which suggests a combined impact of
genetic, lifestyle and/or environmental risk factors.
Knowledge of factors associated with a high T2DM risk can
help identify individuals at greatest need for intensive moni-
toring and intervention. In contrast with general population
studies31, we found that women with SMI had a higher risk for
developing T2DM than men. This finding warrants further
Table 1 Subgroup analyses of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness (continued)
Meta-analysis Heterogeneity
Number
of studies
Pooled T2DM
prevalence (%) 95% CI
Between-group
difference p-value I2 Q p-value
Olanzapine 9 10.6 7.0-15.7 2.5 8.2 0.41
Risperidone 9 13.2 8.8-19.4 54.2 17.4 0.026
Quetiapine 7 16.0 9.9-24.7 0 2.5 0.87
Aripiprazole 3 6.7 1.5-25.0 0 0.3 0.87
Amisulpride 2 3.9 0.5-25.0 0 0.6 0.44
Typical antipsychotics 11 10.6 7.0-15.7 57.8 23.7 0.008
Significant between-group differences are highlighted in bold prints
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investigation, but may be related to a greater propensity to
obesity and central obesity in women with SMI compared to
men32, since central obesity is a significant risk factor for
hyperglycaemia. On the other hand, only a minority of ana-
lyzed studies did provide information about the mean age in
women and men, and it is possible that women with schizo-
phrenia were older, which could have confounded the results.
Our results also show that T2DM prevalence was higher in
individuals with multi-episode schizophrenia compared with
persons in their first episode. The current meta-analysis adds
to the evidence that a first-episode diagnosis is a unique pre-
dictor of lower T2DM prevalence independent of mean age, a
finding that was also apparent in a recent analysis of metabol-
ic syndrome prevalences across patients with the same three
main SMIs33. Our results point toward the need to adopt a pre-
vention/early intervention approach in order to reduce cardio-
metabolic risk in people with SMI. Further research is needed
to explore the mechanisms underlying this increased T2DM
risk with the transition of the illness from an initial episode to
a multi-episode disorder.
Our data confirm prior evidence that psychotropic medica-
tion use, including that of antidepressants, lithium and anti-
psychotic medications26, is associated with higher T2DM
prevalence. Except for aripiprazole and amisulpride, all anti-
psychotics were associated with a significantly increased
T2DM risk compared to antipsychotic-na€ıve patients. Varia-
tions in the risk for glucose abnormalities are evident in the lit-
erature, with the highest risk being associated with clozapine,
olanzapine and quetiapine in carefully designed studies25,34,35.
In the current meta-analysis, quetiapine (and a trend for
Table 2 Meta-regressions of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness
Moderator Number of comparisons b 95% CI p-value R2
Design (vs. retrospective) 0.02
Cross-sectional 113 20.35 20.72 0.007 0.054
Prospective 64 20.51 21.04 0.008 0.053
Population based (yes/no) 134 20.002 20.34 0.33 0.99 0.00
Setting (vs. mixed) 0.02
Inpatients 74 0.32 20.12 0.77 0.15
Outpatients 73 0.30 20.15 0.76 0.19
Community patients 58 0.19 20.32 0.70 0.47
T2DM assessment (vs. self-report) 0.09
Blood testing 60 20.02 20.53 0.49 0.92
Charts 87 0.63 0.18 1.07 0.006
Publication data (before 2000 or not) 134 20.08 20.56 0.40 0.75 0.00
First episode (yes/no) 81 1.31 0.80 1.81 <0.001 0.19
Mean age (years) 118 0.05 0.03 0.07 <0.001 0.18
Gender (% male) 123 0.25 20.37 0.88 0.42 0.01
Ethnicity (% Caucasian) 37 20.65 21.48 0.17 0.12 0.07
Duration of illness (years) 29 0.03 0.007 0.06 0.01 0.15
Smoking (% smokers) 31 20.24 21.83 1.35 0.77 0.01
Treatment duration (years) 9 0.07 0.03 0.10 <0.001 0.72
Antidepressants use (%) 16 2.82 1.08 4.55 0.001 0.44
Mood stabilizers use (%) 13 20.47 22.09 1.14 0.57 0.06
Lithium use (%) 11 3.07 1.46 4.68 <0.001 0.65
Geographical region (vs. North America) 0.06
Europe 90 20.55 20.96 20.13 0.009
Asia 86 20.23 20.67 0.22 0.31
Australia 63 20.30 21.15 0.55 0.49
South America 63 20.48 21.44 0.48 0.32
Africa 60 20.59 21.93 0.75 0.39
Middle East 60 20.19 21.49 1.12 0.78
Significant p-values are highlighted in bold prints
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clozapine) was associated with an even higher T2DM risk than
olanzapine use. However, this finding should be interpreted
with caution, as order effects cannot be excluded, in that
patients who acquired marked T2DM risk or developed even
frank T2DM on a higher-risk agent, such as olanzapine, could
have been switched to another antipsychotic, including que-
tiapine, potentially leading to risk misattribution.
Finally, as expected, patient self-report yielded numerically
the lowest T2DM prevalences; the T2DM prevalence was sig-
nificantly lower compared with chart review data. This finding
is likely due to the fact that, in chart review studies, patients
were followed back a longer time, extending the detection
period. In line with this interpretation, there was a trend for
retrospective studies to be associated with higher T2DM prev-
alences than prospective ones.
Clinical implications
Our meta-analysis highlighted geographical differences in
T2DM, mirroring the different prevalences in the general pop-
ulation, indicating the possible influence of lifestyle and other
environmental factors with or without genetic risk differences.
Thus, considering the observed increased T2DM risks, screen-
ing for and trying to minimize risk factors (including adverse
lifestyle factors and specific antipsychotic medication choice)
should be a key priority in the multidisciplinary treatment of
people with SMI36-39.
Our data clearly demonstrate that people with SMI should
be considered as a “homogeneous and important high-risk
group” that needs proactive screening for T2DM. It is particu-
larly important to establish baseline T2DM risk at initial pre-
sentation, so that any subsequent change during treatment
can be monitored. The medical history and examination
should, at a minimum, include: a) history of previous CVD,
T2DM or other related diseases; b) family history of premature
CVD, T2DM or other related diseases; c) smoking, dietary and
physical activity habits; d) weight and height in order to calcu-
late body mass index, and waist circumference; e) fasting
blood glucose and/or hemoglobin A1c (HBA1c); f) blood pres-
sure (measured twice and average taken); and g) past medica-
tion history39.
As there are differences in T2DM prevalences across assess-
ment methods, it is recommended that fasting blood glucose
measurements (ideally even oral glucose tolerance testing as
the gold standard) should be obtained prior to the first pre-
scription of antipsychotic medication. The frequency of glu-
cose metabolism testing will depend on the patient’s medical
history and the prevalence of baseline risk factors. For patients
on antipsychotic medication with normal baseline tests, it is
recommended that measurements should be repeated at 12
weeks after initiation of treatment and at least annually there-
after, with more frequent assessments in high-risk patients,
such as those with significant weight gain, post-partum diabe-
tes or a first-degree family history of diabetes40. In patients
with T2DM (and those with pre-diabetes), fasting blood glu-
cose and HBA1c should be measured more frequently (approx-
imately every 3-6 months). An annual examination should
include measurement of CVD risk factors, glomerular filtration
rate and albumin to creatinine ratio, an eye examination, ide-
ally including fundus photography, and foot examination to
diagnose early signs of complications41.
Despite the imperative to screen for T2DM, screening for
T2DM and CVD risk factors is still suboptimal, with only slight
improvement over the last decade12. The low glucose screen-
ing rates (44.3%; 95% CI: 36.3%-52.4%)12 may reflect both
patient and professional barriers. Professional barriers to
screening within mental health settings may on their turn
reflect lack of clarity about whose clinical responsibility the
screening is, lack of understanding about what should be mea-
sured and when, uncertainity about how to interpret results,
and lack of access to necessary equipment41, as well as incom-
plete communication between primary and secondary care.
Without systematic screening following detailed recommenda-
tions and using acceptable and accurate diagnostic tests, the
true prevalence of T2DM in patients with SMI will remain
unknown and underestimated.
Even after an established diagnosis of T2DM is made, many
of those with mental ill health are not offered timely treat-
ment42. Thus, it should be clarified that routine screening is
only the first step. Psychiatric centers should cooperate with
diabetes centers to establish shared care pathways and ensure
an integrated approach for people with mental illness and
T2DM. Such an approach would reflect recent calls for the
breaking down of the traditional “silo” approach to physical
and mental health care, in line with the internationally
endorsed Healthy Active Lives Declaration (www.iphys.org).
Those with diagnosed T2DM should also be seen regularly
by a multidisciplinary team, including physicians, diabetes
nurses, physical therapists or exercise physiologists and dieti-
cians, to advise not just on diabetes but also on other risk fac-
tors and medical comorbidities.
When T2DM is detected, people with SMI are likely to require
additional pharmacological management, but this is unlikely to
be significantly different from the general population. However,
clinicians should be aware that any deterioration in mental
health may result in compromised management of T2DM, and
comprehensive management may require an adjustment to the
diabetes care plan.
Limitations
Whilst this is the most comprehensive and thorough meta-
analysis of T2DM in people with SMI conducted to date, we
acknowledge some limitations that largely reflect problems in
the primary data.
First, only a limited number of studies assessed T2DM using
an oral glucose tolerance test as the gold standard. There are
inherent problems with using chart reviews in relation to
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selection bias and the reliability and validity of the T2DM diag-
nosis. Second, because our study findings were mainly based on
cross-sectional rather than longitudinal data, directionality of
the association between medication use and observed T2DM
risk cannot be deduced with certainty; that is, it is possible that
those with inherently higher metabolic risk factors may be more
likely to receive antipsychotics. Also, given that many of the
studies reported cross-sectional data, it is possible that people
with SMI deemed to be at particular risk for glucose abnormali-
ties were preferentially prescribed antipsychotics perceived to
be of lower risk, such as aripiprazole and amisulpride.
Third, variables such as clinical subtypes of MDD and bipo-
lar disorder were not reported and controlled for. Fourth, a
threat to the validity of any meta-analysis is publication bias
and heterogeneity, which we encountered in most of our ana-
lyses. Nevertheless, we adjusted for publication bias using the
trim and fill analysis, and were able to explain over half of
the between-study heterogeneity in our multivariable meta-
regression analysis. Fifth, there were inadequate data on life-
style behaviors, precluding meta-analytic assessment of these
factors as moderating or mediating variables.
Future research
Since antipsychotic medications are increasingly used as
first line treatments for bipolar disorder43 and MDD44, addi-
tional research on the underlying mechanisms for the develop-
ment of hyperglycaemia after pharmacotherapy initiation is
needed. Moreover, future studies should examine whether dif-
ferent clinical subtypes of depression (i.e. melancholic, psy-
chotic, atypical or undifferentiated) and bipolar disorder (e.g.
type 1 or 2), specific mood states (manic, depressive, mixed or
euthymic), or different antidepressants or mood stabilizers sig-
nificantly moderate T2DM risk. For example, previous studies45
found that some antidepressants may, in some circumstances,
reduce hyperglycaemia, normalize glucose homeostasis and
also increase insulin sensitivity, whereas others, including tricy-
clic antidepressants, may exacerbate glycaemic dysfunction or
have little effect on glucose homeostasis46,47.
Furthermore, the pathophysiology underlying the associa-
tion between SMI and T2DM is complex and not well under-
stood, requiring further investigation. Emerging evidence48
suggests that SMI and T2DM share some pathophysiological
features, including hypothalamic-pituitary-adrenal and mito-
chondrial dysfunction, neuro-inflammation, common genetic
links and epigenetic interactions.
Future research should also comprehensively assess T2DM
risk factors, and evaluate the optimal monitoring regimen and
interventions. Finally, long-term follow-up is required to accu-
rately document the emergence of more distal outcomes, such
as ischemic heart disease, medical costs, and premature
mortality49.
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